Meeting
2022 ASCO Gastrointestinal Cancers Symposium
Safety, tolerability, and preliminary antitumor activity of sitravatinib plus tislelizumab (TIS) in patients (pts) with unresectable locally advanced or metastatic gastric cancer/gastroesophageal junction cancer (GC/GEJC).
Authors
Zhendong Chen
The Second Hospital of Anhui Medical Hospital, Hefei, China
Zhendong Chen , Yuxian Bai , Tao Zhang , Jieer Ying , Xiaoyan Lin , Liu Yang , Jun Wang , Juan Zhang , Fan Yu , Cong Fei , Ruiqi Huang , Jin Li
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session A: Cancers of the Esophagus and Stomach and Other GI Cancers
Track
Esophageal and Gastric Cancer,Other GI Cancer
Sub Track
Therapeutics
Clinical Trial Registration Number
NCT03941873
DOI
10.1200/JCO.2022.40.4_suppl.281
Abstract #
281
Poster Bd #
Online Only
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Gastrointestinal Cancers Symposium
Safety, tolerability, and preliminary antitumor activity of sitravatinib plus tislelizumab (TIS) in patients (pts) with unresectable locally advanced or metastatic hepatocellular carcinoma (HCC).
First Author: Feng Zhang
Poster
2023 ASCO Gastrointestinal Cancers Symposium
An open-label, single-arm, dose escalation and expansion phase 1 study of tebotelimab (MGD013) plus niraparib in patients with locally advanced or metastatic gastric cancer who failed prior treatments.
First Author: Miaozhen Qiu
Poster
2023 ASCO Gastrointestinal Cancers Symposium
Camrelizumab combined with apatinib and albumin-bound paclitaxel followed by camrelizumab plus apatinib as first-line therapy for unresectable or metastatic pancreatic cancer.
First Author: Bo Shen
Poster
2022 ASCO Annual Meeting
A phase II study to evaluate the efficacy and safety of camrelizumab plus famitinib in advanced or metastatic thyroid cancer.
First Author: Dongmei Ji